GlassScriptPhysician profile
Heather A Howell
NPI 1063981272
$15,654.21
in general payments reported to CMS, 2019-2025
30 companies · $2,931 in 2025
The $2,931 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,557 · 2022: $2,908 · 2023: $2,906 · 2024: $5,352 · 2025: $2,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,511 · Consulting Fee: $1,586 · Education: $66.99 · Travel and Lodging: $25.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,510.83 |
| Consulting Fee | $1,586.00 |
| Education | $66.99 |
| Travel and Lodging | $25.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,731.12 | 2021-2025 | |
| Janssen Biotech, INC. | $2,599.70 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,435.18 | 2021-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $997.09 | 2021-2025 | |
| Lilly USA, LLC | $938.34 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $778.18 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $714.20 | 2021-2025 | |
| Pfizer INC. | $687.63 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $525.41 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $525.15 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $476.29 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Galderma Laboratories, L.P. | $422.62 | 2021-2025 | Nemluvio |
| Amgen INC. | $384.99 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $374.25 | 2021-2025 | Opzelura |
| Almirall LLC | $265.73 | 2021-2024 | Seysara |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $250.46 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $206.20 | 2023-2024 | Vtama |
| Allergan, INC. | $191.10 | 2021-2022 | |
| Kerecis Limited | $185.69 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Journey Medical Corporation | $158.45 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.37 | 2022-2024 | Arazlo, Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $145.19 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $140.00 | 2021 | |
| Convatec INC. | $95.50 | 2024 | |
| Janssen Pharmaceuticals, INC | $94.89 | 2024 | Tremfya |
| Biofrontera INC. | $63.22 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $47.19 | 2024-2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.89 | 2025 | Spevigo |
| Integra Lifesciences Corporation | $22.19 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Mallinckrodt Hospital Products INC. | $16.99 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.